Search results for "Dysplastic"

showing 10 items of 90 documents

Correlation between hypertrophy and risk of hypertension in congenital solitary functioning kidney

2018

Purpose: Solitary functioning kidney (SFK) may be associated to hypertrophy, hypertension and chronic kidney disease. We evaluated blood pressure (BP) of children with congenital SFK comparing agenesis to multicystic dysplastic kidney (MCDK) and correlated BP profiles with renal dimensions of affected and contralateral kidney. Methods: We compared 40 patients with MCDK, grouped for either treatment options (A: conservative vs B: nephrectomy) or involution time (A1: before 4 years-of-age vs A2: persistence-of-MCDK), to 10 unilateral agenesis (C). Patients were evaluated with ultrasound, scintigraphy, office-ambulatory BP monitoring. Results: Compensatory hypertrophy was demonstrated in most …

Malemedicine.medical_specialtyMulticystic dysplastic kidneyAmbulatory blood pressurePrognosiRenal Hypertrophymedicine.medical_treatmentMulticystic dysplastic kidneyUrologyBlood PressureMuscle hypertrophySolitary Kidney03 medical and health sciences0302 clinical medicine030225 pediatricsHumansMedicineChildUltrasonographybusiness.industryCongenital solitary functioning kidneyHypertrophyGeneral MedicineBlood Pressure Monitoring AmbulatoryPrognosismedicine.diseaseNephrectomyBlood pressureRenal hypertrophyAgenesisHypertensionPediatrics Perinatology and Child HealthFemale030211 gastroenterology & hepatologySurgerybusinessHumanKidney diseasePediatric Surgery International
researchProduct

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

2009

Background Acquired somatic deletions and loss-of-function mutations in one or several codons of the TET2 ( Ten-Eleven Translocation-2 ) gene were recently identified in hematopoietic cells from patients with myeloid malignancies, including myeloproliferative disorders and myelodys-plastic syndromes. The present study was designed to determine the prevalence of TET2 gene alterations in chronic myelomonocytic leukemias. Design and Methods Blood and bone marrow cells were collected from 88 patients with chronic phase chronic myelomonocytic leukemia and from 14 with acute transformation of a previously identified disease. Polymerase chain reaction analysis and direct sequencing were used to se…

Malemedicine.medical_specialtyMyeloidDNA Mutational AnalysisChronic myelomonocytic leukemiaSingle-nucleotide polymorphismKaplan-Meier EstimateGene mutationBiologymedicine.disease_causeDioxygenasesGene FrequencyMonocytosisInternal medicinehemic and lymphatic diseasesProto-Oncogene ProteinsmedicineHumansGenetic Predisposition to DiseaseLetters to the EditorAgedProportional Hazards ModelsAged 80 and overComparative Genomic HybridizationMutationHematologyLeukemia Myelomonocytic ChronicHematologyMiddle Agedmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesDNA-Binding ProteinsLeukemiamedicine.anatomical_structureImmunologyMutationFemaleOriginal Article
researchProduct

Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project

2010

AbstractChanging definitions and classifications of hematologic malignancies (HMs) complicate incidence comparisons. HAEMACARE classified HMs into groupings consistent with the latest World Health Organization classification and useful for epidemiologic and public health purposes. We present crude, age-specific and age-standardized incidence rates for European HMs according to these groupings, estimated from 66 371 lymphoid malignancies (LMs) and 21 796 myeloid malignancies (MMs) registered in 2000-2002 by 44 European cancer registries, grouped into 5 regions. Age-standardized incidence rates were 24.5 (per 100 000) for LMs and 7.55 for MMs. The commonest LMs were plasma cell neoplasms (4.6…

Malemedicine.medical_specialtyPathologyChildhood leukemiaHematologic malignant; Europe; morphologic subtype; international comparison; population-based cancer registry.ImmunologyPopulationUNITED-STATESALCOHOLBiochemistryNOMyelodysplastic–myeloproliferative diseasesInternal medicineEpidemiologymorphologymedicineLYMPHOMAHumansEPIDEMIOLOGYRegistriesEXPOSUREeducationRISKeducation.field_of_studyTOBACCOhaematologic malignanciesbusiness.industryIncidence (epidemiology)IncidenceleukemiaMyeloid leukemiaCell BiologyHematologyHematologic malignancies; morphology; Europe.Plasma cell neoplasmmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesLymphomaEuropeCANCER INCIDENCEHematologic Neoplasmscancer incidence tobacco alcohol epidemiology leukemia risk exposureCHILDHOOD LEUKEMIAHematologic malignanciesFemalebusiness
researchProduct

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent…

2015

Summary Background Acute myeloid leukaemia mainly affects elderly people, with a median age at diagnosis of around 70 years. Although about 50–60% of patients enter first complete remission upon intensive induction chemotherapy, relapse remains high and overall outcomes are disappointing. Therefore, effective post-remission therapy is urgently needed. Although often no post-remission therapy is given to elderly patients, it might include chemotherapy or allogeneic haemopoietic stem cell transplantation (HSCT) following reduced-intensity conditioning. We aimed to assess the comparative value of allogeneic HSCT with other approaches, including no post-remission therapy, in patients with acute…

Malemedicine.medical_specialtyTransplantation ConditioningGemtuzumab ozogamicinmedicine.medical_treatmentAntibodies Monoclonal HumanizedCOUNCIL AML11 TRIALEUROPEAN LEUKEMIANETInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointINDUCTION CHEMOTHERAPYHumansTransplantation HomologousProspective StudiesADULT PATIENTS610 Medicine & healthBusulfanMETAANALYSISAgedMYELODYSPLASTIC SYNDROMEChemotherapyRISK-ADAPTED APPROACHbusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInduction chemotherapyHematology1ST COMPLETE REMISSIONTotal body irradiationMiddle AgedGemtuzumabGEMTUZUMAB OZOGAMICINSurgeryFludarabineTransplantationSurvival RateLeukemia Myeloid AcuteAminoglycosidesTreatment OutcomeSURVIVALFemaleNeoplasm Recurrence LocalbusinessBusulfanVidarabinemedicine.drugLancet. Haematology
researchProduct

Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations.

2009

Chromosome 1 is the largest human chromosome and contains over 1600 known genes and 1000 novel coding sequences or transcripts. It is, therefore, not surprising that recurrent chromosome 1 abnormalities are regularly encountered in both neoplastic and non-neoplastic medical conditions. The current review is focused on myeloid malignancies where we summarize the relevant published literature and discuss specific karyotype-phenotype associations. We show that chromosome 1 abnormalities are most frequent in BCR-ABL-negative classic myeloproliferative neoplasms (MPN): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Specific abnormalities include duplicat…

MyeloidChromosomal translocationBiologyTranslocation GeneticSettore MED/15 - Malattie Del Sanguehemic and lymphatic diseasesmedicineHumansGenes Tumor SuppressorMyelofibrosisGeneticsChromosome AberrationsMyeloproliferative DisordersEssential thrombocythemiaMyelodysplastic syndromesMyeloid leukemiaKaryotypeHematologyGeneral MedicineOncogenesmedicine.diseasemedicine.anatomical_structurePhenotypeChromosomes Human Pair 1Leukemia MyeloidKaryotypingMyelodysplastic Syndromeschomosome 1 myeloid malignancyChromosome DeletionLiterature surveyEuropean journal of haematology
researchProduct

Constant detection of cyclooxygenase 2 in terminal stages of myeloid maturation.

2006

MyeloidNeutrophilsCellular differentiationApoptosisBone Marrow Cellsmyeloid maturation.Myeloproliferative DisordersBone MarrowReference ValuesMedicineHumansMyeloid CellsErythroid Precursor CellsErythroid Precursor CellsMyeloproliferative Disordersbiologybusiness.industryMembrane ProteinsCell DifferentiationHematologyGeneral MedicineCell biologyHematopoiesisHaematopoiesismedicine.anatomical_structureBiochemistryMembrane proteinApoptosisCyclooxygenase 2Myelodysplastic Syndromesbiology.proteinCyclooxygenasebusinessMegakaryocytes
researchProduct

Unilateral multicystic dysplastic kidney in infants exposed to antiepileptic drugs during pregnancy

2007

Prenatal exposure to antiepileptic drugs (AEDs) increases the risk of major congenital malformations (MCM) in the fetus. AED-related abnormalities include heart and neural tube defects, cleft palate, and urogenital abnormalities. Among the various congenital anomalies of the kidney and urinary tract (CAKUT), multicystic dysplastic kidney (MCDK) disease is one of the most severe expressions. Although prenatal ultrasound (US) examination has increased the prenatal diagnosis of MCDK, the pathogenesis is still unclear. We report on four cases of MCDK in infants of epileptic women treated with AEDs during pregnancy. From October 2003 to June 2006, we observed four infants with unilateral MCDK bo…

Nephrologymedicine.medical_specialtyTime FactorsVoiding cystourethrogramUrinary systemMulticystic dysplastic kidneyPrenatal diagnosisUltrasonography PrenatalPregnancyInternal medicineProhibitinsmedicineHumansMulticystic Dysplastic KidneyMaternal-Fetal ExchangeFetusPregnancyEpilepsymedicine.diagnostic_testbusiness.industryObstetricsInfant Newbornmedicine.diseaseSurgeryMulticystic dysplastic kidney . Antiepileptic drugs . Major congenital anomalies . InfantCarbamazepineTreatment OutcomeNephrologyPhenobarbitalPrenatal Exposure Delayed EffectsPediatrics Perinatology and Child HealthGestationAnticonvulsantsFemalebusinessFollow-Up Studies
researchProduct

Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France.

2012

Long-term population-based survival data detailed by cancer subtype are important to measure the overall outcomes of malignancy managements. We provide net survival estimates at 1, 3, 5 and 10-year postdiagnosis on 37,549 hematological malignancy (HM) patients whose ages were >15 years, diagnosed between 1989 and 2004 and actively followed until 2008 by French population-based cancer registries. These are, to our knowledge, the first unbiased estimates of 10-year net survival in HMs detailed by subtypes. HMs were classified according to the International Classification of Diseases-Oncology 3. Net survival was estimated with the unbiased Pohar-Perme method. The results are reported by sex an…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationFollicular lymphomaMalignancyAge DistributionBiasInternal medicinemedicineHumansRegistriesSex DistributioneducationAgededucation.field_of_studyLeukemiaModels Statisticalbusiness.industryMortality rateLymphoma Non-HodgkinCancerMiddle Agedmedicine.diseasePrognosisHodgkin DiseaseLymphomaCancer registryOncologyHematologic NeoplasmsMyelodysplastic SyndromesImmunologyFemaleFrancebusinessChronic myelogenous leukemiaInternational journal of cancer
researchProduct

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypometh…

2017

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

OncologyAdultMalemedicine.medical_specialtyAntimetabolites AntineoplasticeducationAzacitidineChronic myelomonocytic leukemiaDecitabine03 medical and health sciences0302 clinical medicineMyelodysplastic–myeloproliferative diseaseshemic and lymphatic diseasesInternal medicinemedicineHumansLetter to the Editorhealth care economics and organizationsAgedHematologybusiness.industryMyelodysplastic syndromesTranslational biologyfood and beveragesLeukemia Myelomonocytic Chronic[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyDNA MethylationMiddle Agedmedicine.diseaseMyelodysplastic-Myeloproliferative DiseasesSurvival Analysis3. Good healthResponse assessmentLeukemiaTreatment OutcomeOncology030220 oncology & carcinogenesisMyelodysplastic SyndromesImmunologyAzacitidineFemalebusiness030215 immunologymedicine.drug
researchProduct

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.

2013

The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transplantation (n=167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R.

OncologyAdultMalemedicine.medical_specialtyPediatricsCancer ResearchScoring systemAllogeneic transplantationSurvivalAdolescenturologic and male genital diseasesRisk AssessmentIPSS; IPSS-R; MDS; Prognosis; Survival; WPSS; Hematology; Oncology; Cancer ResearchRisk categoryYoung AdultRisk FactorsInternal medicinemedicineMDSHumansIn patientAgedAged 80 and overIPSS-Rbusiness.industryIPSSInduction chemotherapyReproducibility of ResultsHematologyMiddle AgedPrognosisSurvival AnalysisMulticenter studyOncologyInternational Prognostic Scoring SystemLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseMultivariate AnalysisDisease ProgressionWPSSFemalebusinessLeukemia research
researchProduct